Actualités id6162.html
Awaiting development: Guidance and quality standards
Fri, 01 Nov 2024 18:31:00 GMT
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162] Technology appraisal guidance Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell ...